Tibet Rhodiola Pharmaceutical Holding Co Cash Flow-to-Debt Ratio
Tibet Rhodiola Pharmaceutical Holding Co cash flow-to-debt ratio. Tibet Rhodiola Pharmaceutical Holding Co (600211) has a Cash Flow-to-Debt Ratio of 0.14x as of December 2025, meaning its operating cash flow of CN¥297.86 Million could theoretically repay 0% of its total liabilities (CN¥2.10 Billion) in one year. Check Tibet Rhodiola Pharmaceutical Holding Co (600211) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Tibet Rhodiola Pharmaceutical Holding Co (1999–2025)
Cash flow-to-debt ratio of Tibet Rhodiola Pharmaceutical Holding Co from 1999 to 2025. Historical debt coverage capacity for Tibet Rhodiola Pharmaceutical Holding Co across 27 annual periods. Check 600211 cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Tibet Rhodiola Pharmaceutical Holding Co Cash Flow-to-Debt Ratio by Year (1999–2025)
Tibet Rhodiola Pharmaceutical Holding Co cash flow-to-debt ratio by year from 1999 to 2025. Year-by-year debt coverage analysis for Tibet Rhodiola Pharmaceutical Holding Co. For the full cash flow conversion analysis, see how efficiently does Tibet Rhodiola Pharmaceutical Holding Co generate cash.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.49x | CN¥1.03 Billion | CN¥2.10 Billion | ▼ -60.9% |
| 2024 | 1.25x | CN¥994.79 Million | CN¥795.23 Million | ▲ +40.3% |
| 2023 | 0.89x | CN¥1.08 Billion | CN¥1.21 Billion | ▲ +13.8% |
| 2022 | 0.78x | CN¥837.38 Million | CN¥1.07 Billion | ▲ +147.5% |
| 2021 | 0.32x | CN¥366.53 Million | CN¥1.16 Billion | ▼ -73.7% |
| 2020 | 1.20x | CN¥428.17 Million | CN¥355.91 Million | ▼ -21.3% |
| 2019 | 1.53x | CN¥489.59 Million | CN¥320.44 Million | ▲ +45.2% |
| 2018 | 1.05x | CN¥289.22 Million | CN¥274.89 Million | ▲ +227.4% |
| 2017 | 0.32x | CN¥91.46 Million | CN¥284.64 Million | ▲ +109.6% |
| 2016 | 0.15x | CN¥250.21 Million | CN¥1.63 Billion | ▼ -74.8% |
| 2015 | 0.61x | CN¥133.93 Million | CN¥220.43 Million | ▲ +371.7% |
| 2014 | -0.22x | CN¥-141.40 Million | CN¥632.26 Million | ▼ -159.1% |
| 2013 | 0.38x | CN¥279.22 Million | CN¥738.26 Million | ▲ +209.4% |
| 2012 | 0.12x | CN¥56.20 Million | CN¥459.72 Million | ▲ +337.8% |
| 2011 | 0.03x | CN¥12.09 Million | CN¥432.93 Million | ▲ +504.5% |
| 2010 | 0.00x | CN¥1.90 Million | CN¥411.28 Million | ▼ -88.5% |
| 2009 | 0.04x | CN¥17.88 Million | CN¥443.70 Million | ▲ +3.4% |
| 2008 | 0.04x | CN¥21.46 Million | CN¥550.51 Million | ▲ +218.8% |
| 2007 | -0.03x | CN¥-18.30 Million | CN¥557.68 Million | ▼ -145.9% |
| 2006 | 0.07x | CN¥33.63 Million | CN¥470.56 Million | ▲ +61.4% |
| 2005 | 0.04x | CN¥18.92 Million | CN¥427.37 Million | ▼ -43.8% |
| 2004 | 0.08x | CN¥26.90 Million | CN¥341.74 Million | ▼ -45.0% |
| 2003 | 0.14x | CN¥47.20 Million | CN¥329.82 Million | ▲ +36.9% |
| 2002 | 0.10x | CN¥32.85 Million | CN¥314.23 Million | ▲ +36.4% |
| 2001 | 0.08x | CN¥15.47 Million | CN¥201.82 Million | ▼ -53.0% |
| 2000 | 0.16x | CN¥20.55 Million | CN¥126.01 Million | ▲ +239.2% |
| 1999 | 0.05x | CN¥2.25 Million | CN¥46.73 Million | — |